# Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

> **NCT00463203** · PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 54 (estimated)

## Conditions studied

- Brain Neoplasms
- Glioma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00463203
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-06
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2011-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463203, "Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00463203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*